Experienced in Thalassemia

Dr. Wangjian Zhong

Hematology Oncology | Hematology | Oncology
Baptist Health Medical Group Inc
2400 Eastpoint Pkwy, 
Louisville, KY 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Experienced in Thalassemia
Baptist Health Medical Group Inc
2400 Eastpoint Pkwy, 
Louisville, KY 
OverviewInsuranceLocationsClinical Research

Overview

Wangjian Zhong is a Hematologist Oncology specialist and a Hematologist in Louisville, Kentucky. Dr. Zhong and is rated as an Experienced provider by MediFind in the treatment of Thalassemia. His top areas of expertise are Childhood Iron Deficiency Anemia, Anal Cancer, Lung Cancer, and Iron Deficiency Anemia. Dr. Zhong is currently accepting new patients.

His clinical research consists of participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in KY
Hospital Affiliations
Baptist Health Lagrange
Baptist Health Hardin
Baptist Health Louisville
Languages Spoken
English
Mandarin
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Anthem
  •  CareSource
  •  Humana

Locations

BAPTIST HEALTH MEDICAL GROUP INC
2400 Eastpoint Pkwy, Louisville, KY 40223
Other Locations
BAPTIST HEALTH MEDICAL GROUP INC
4002 Kresge Way, Suite 110, Louisville, KY 40207
BAPTIST HEALTH MEDICAL GROUP INC
4003 Kresge Way, Louisville, KY 40207
BAPTIST HEALTH MEDICAL GROUP INC
1025 New Moody Ln, La Grange, KY 40031

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
Enrollment Status: Recruiting
Publish Date: January 29, 2025
Intervention Type: Drug
Study Drugs: N-803, Pembrolizumab, Nivolumab, Atezolizumab, Avelumab, Durvalumab, PD-L1 t-haNK
Study Phase: Phase 2
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Other, Drug
Study Drugs: Cisplatin, Veliparib
Study Phase: Phase 2
A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients With Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as Intermediate or High Risk by a 14-Gene Prognostic Assay
A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients With Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as Intermediate or High Risk by a 14-Gene Prognostic Assay
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2025
Intervention Type: Drug, Other
Study Drug: Adjuvant Chemotherapy
Study Phase: Not Applicable
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: January 30, 2025
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drugs: Zimberelimab, Domvanalimab, Etrumadenant
Study Phase: Phase 2
An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 29, 2024
Intervention Type: Drug
Study Drugs: Itacitinib, Osimertinib
Study Phase: Phase 1/Phase 2
QUILT 2.023: A Phase 3, Open-Label, 3-Cohort Randomized Study of N-803, in Combination With Current Standard of Care VS Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic NSCLC.
QUILT 2.023: A Phase 3, Open-Label, 3-Cohort Randomized Study of N-803, in Combination With Current Standard of Care VS Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic NSCLC.
Enrollment Status: Active_not_recruiting
Publish Date: August 14, 2024
Intervention Type: Drug
Study Drugs: N-803+Pembrolizumab, N-803+Carboplatin+Nab-paclitaxel+Pembrolizumab, N-803+Cisplatin or Carboplatin+Pembrolizumab+Pemetrexed, Pembrolizumab, Carboplatin+Nab-paclitaxel or Paclitaxel+Pembrolizumab, Cisplatin or Carboplatin+Pembrolizumab+Pemetrexed
Study Phase: Phase 3
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2024
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Phase 1b/2 Study of Viagenpumatucel-L (HS-110) in Combination With Multiple Treatment Regimens in Patients With Non-Small Cell Lung Cancer (The DURGA Trial)
A Phase 1b/2 Study of Viagenpumatucel-L (HS-110) in Combination With Multiple Treatment Regimens in Patients With Non-Small Cell Lung Cancer (The DURGA Trial)
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Biological, Drug
Study Drugs: Viagenpumatucel-L, Nivolumab, Pembrolizumab, Pemetrexed
Study Phase: Phase 1/Phase 2
The Circulating Cell-free Genome Atlas Study
The Circulating Cell-free Genome Atlas Study
Enrollment Status: Active_not_recruiting
Publish Date: September 13, 2023
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Enrollment Status: Completed
Publish Date: September 01, 2022
Intervention Type: Other
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Hematologic Malignancies
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Hematologic Malignancies
Enrollment Status: Terminated
Publish Date: February 03, 2021
Intervention Type: Other
View 11 Less Clinical Trials
Similar Doctors
Advanced in Thalassemia
Dr. Elisabeth C. Von Bun
Hematology Oncology | Hematology | Oncology
Advanced in Thalassemia
Dr. Elisabeth C. Von Bun
Hematology Oncology | Hematology | Oncology
301 Gordon Gutmann Blvd, Suite 301, 
Jeffersonville, IN 
 (11.8 mi)
812-288-9969
Languages Spoken:
English, German, Hindi
See accepted insurances
Accepting New Patients

Elisabeth Von Bun is a Hematologist Oncology specialist and a Hematologist in Jeffersonville, Indiana. Dr. Von Bun and is rated as a Distinguished provider by MediFind in the treatment of Thalassemia. Her top areas of expertise are Hodgkin Lymphoma, Paget Disease of the Breast, Intraductal Papilloma, and Pleuropulmonary Blastoma. Dr. Von Bun is currently accepting new patients.

Experienced in Thalassemia
Dr. Donald E. Goodin
Hematology Oncology | Hematology | Oncology
Experienced in Thalassemia
Dr. Donald E. Goodin
Hematology Oncology | Hematology | Oncology

Baptist Health Medical Group Inc

521 Robinbrooke Blvd, 
Elizabethtown, KY 
 (44.3 mi)
270-706-1535
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Donald Goodin is a Hematologist Oncology specialist and a Hematologist in Elizabethtown, Kentucky. Dr. Goodin and is rated as a Distinguished provider by MediFind in the treatment of Thalassemia. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, Non-Small Cell Lung Cancer (NSCLC), and Lung Cancer. Dr. Goodin is currently accepting new patients.

Experienced in Thalassemia
Dr. Ignacio Montes
Hematology Oncology | Hematology | Oncology
Experienced in Thalassemia
Dr. Ignacio Montes
Hematology Oncology | Hematology | Oncology
4003 Kresge Way, Ste 500, 
Louisville, KY 
 (7.8 mi)
502-897-1166
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Ignacio Montes is a Hematologist Oncology specialist and a Hematologist in Louisville, Kentucky. Dr. Montes and is rated as a Distinguished provider by MediFind in the treatment of Thalassemia. His top areas of expertise are Thrombocytopenia, Opitz G BBB Syndrome, Chronic Lymphocytic Leukemia (CLL), Paget Disease of the Breast, and Bone Marrow Aspiration. Dr. Montes is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile